Our teams have undertaken a number of sponsored trials. For information on setting new clinical trials, please contact:
Here are some examples of past studies:
VICTORIA Study Led by Dr Dinna Soon (Cardiology)
KTPH participated in the industry-sponsored clinical trial, VICTORIA, from 2016 to 2019. A total of 5050 chronic heart failure patients participated globally.
Results showed that subjects treated with Vericiguat in addition to standard of care had a 10% lower risk of cardiovascular death or first heart failure hospitalization. To date, no known therapies have been able to reduce the risk of hospitalization after a worsening event. Through this study, the novel Vericiguat could help bridge this gap.
FIDELIO-DKD Study Led by A/Prof Sum Chee Fang (Diabetes Centre)
From 2015 to 2019, KTPH participated in the largest industry-sponsored Phase III clinical trial program to date in Chronic Kidney Disease (CKD) and Type II diabetes (T2D); with more than 13,000 patients participating worldwide. CKD is a deadly complication of T2D that affects 4 in 10 patients with T2D.
Results from this study showed that patients given the investigational drug, Finerenone, in addition to their standard of care, had a significant reduction in the time to first occurrence of kidney failure or renal death. Furthermore, when evaluating the composite time to first occurrence, Finerenone was also found to reduce the risk of non-fatal stroke, non-fatal myocardial infarction, cardiovascular (CV) death or heart failure hospitalization.